San Rocco Therap LLC v. Bluebird Bio Inc

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: San Rocco Therapeutics, LLC (Delaware)
  • Defendant: Bluebird Bio, Inc. (Delaware); Third Rock Ventures, LLC (Delaware)
  • Plaintiff's Counsel: Young Conaway Stargatt & Taylor, LLP
• Case Identification: 1:21-cv-01478, D. Del., 03/11/2022
• Venue Allegations: Venue is asserted as proper in the District of Delaware because both Defendants are incorporated in Delaware and are therefore alleged to "reside" in the district for purposes of patent venue.
• Core Dispute: Plaintiff alleges that Defendants' betibeglogene autotemcel (beti-cel) gene therapy, which is manufactured using the BB305 lentiviral vector, infringes patents related to recombinant vectors designed for the treatment of hemoglobinopathies.
• Technical Context: The technology involves gene therapy, specifically the use of lentiviral vectors to introduce a functional human globin gene into a patient's own hematopoietic stem cells to treat inherited blood disorders like Beta Thalassemia and Sickle Cell Disease.
• Key Procedural History: The complaint details a complex history between the parties, including a 2020 settlement agreement arising from prior state court litigation over alleged trade secret misappropriation and conspiracy. Pursuant to that settlement, patent owner Memorial Sloan-Kettering Cancer Center (MSKCC) granted Plaintiff San Rocco Therapeutics an exclusive commercial license to the patents-in-suit, which Plaintiff asserts provides it with standing to bring this infringement action.

Case Timeline

Date	Event
2001-06-29	Priority Date for '179 and '061 Patents
2009-06-02	U.S. Patent No. 7,541,179 ('179 Patent) Issued
2010-09-09	Genetix Pharmaceuticals, Inc. changes name to bluebird bio, Inc.
2011-11-15	U.S. Patent No. 8,058,061 ('061 Patent) Issued
2015-01-01	Bluebird files patent citing the '179 Patent's publication as prior art
2015-01-01	FDA grants Breakthrough Therapy designation to Bluebird's product
2020-11-02	Settlement Agreement executed, granting SRT exclusive license to patents
2021-09-01	Bluebird completes submission of Biologics License Application (BLA) to FDA
2022-03-11	Complaint Filing Date

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 7,541,179 - "Vector Encoding Human Globin Gene And Use Thereof In Treatment Of Hemoglobinopathies"

• Patent Identification: U.S. Patent No. 7,541,179, "Vector Encoding Human Globin Gene And Use Thereof In Treatment Of Hemoglobinopathies," issued June 2, 2009. Compl. ¶14

The Invention Explained

• Problem Addressed: The patent's background section notes that existing treatments for severe hemoglobinopathies like β-thalassemia are either burdensome and imperfect (e.g., blood transfusions) or carry significant risks and are not widely available (e.g., allogeneic bone marrow transplants), creating a need for improved therapeutic approaches. '179 Patent, col. 1:26-35
• The Patented Solution: The invention is a recombinant lentiviral vector designed to provide a genetic correction. It achieves this by carrying not only a "functional globin gene" but also "large portions of the β-globin locus control regions" (LCR), specifically including hypersensitive sites HS2, HS3, and HS4. This combination of the therapeutic gene and its key regulatory elements is intended to enable sustained, high-level protein expression after being delivered into a patient's own hematopoietic stem cells. '179 Patent, abstract '179 Patent, col. 1:45-58
• Technical Importance: The ability to package and successfully transfer large, complex genomic regulatory sequences along with a therapeutic gene was a critical step in developing gene therapies capable of producing therapeutically meaningful levels of protein expression. '179 Patent, col. 1:40-44

Key Claims at a Glance

• The complaint asserts independent claims 1 and 23. Compl. ¶186
• Independent Claim 1 includes the following essential elements:
  • A recombinant vector comprising a nucleic acid encoding a functional globin.
  • The nucleic acid is operably linked to a 3.2-kb nucleotide fragment.
  • This fragment "consists essentially of" three contiguous nucleotide fragments from a human β-globin LCR: a BstXI and SnaBI HS2-spanning fragment, a BamHI and HindIII HS3-spanning fragment, and a BamHI and BanII HS4-spanning fragment.
  • The vector provides for the expression of the globin in a mammal in vivo. Compl. ¶184
• Independent Claim 23 is similar to claim 1 but adds further specificity, requiring:
  • The HS3-spanning and HS4-spanning nucleotide fragments are "adjacent to each other."
  • The vector further comprises "2 GATA-1 binding sites at the junction" between the HS3 and HS4 fragments. Compl. ¶185
• The complaint does not explicitly reserve the right to assert dependent claims for the '179 patent.

U.S. Patent No. 8,058,061 - "Vector Encoding Human Globin Gene And Use Thereof In Treatment Of Hemoglobinopathies"

• Patent Identification: U.S. Patent No. 8,058,061, "Vector Encoding Human Globin Gene And Use Thereof In Treatment Of Hemoglobinopathies," issued November 15, 2011. Compl. ¶16

The Invention Explained

• Problem Addressed: As a divisional of the application that led to the '179 Patent, this patent addresses the same fundamental problem of needing a more effective and less risky long-term treatment for hemoglobinopathies. '061 Patent, col. 1:24-35
• The Patented Solution: Rather than claiming the vector itself, this patent claims the product of the gene therapy process: the patient's own cells after they have been modified. The invention is an "isolated mammalian hematopoietic progenitor cell or an isolated mammalian stem cell" that contains the recombinant lentiviral vector described in the parent patent. It also claims the method of producing these modified cells. '061 Patent, abstract '061 Patent, claims 1, 11
• Technical Importance: Claiming the modified cell and the method of making it provides a different and crucial layer of intellectual property protection, covering the final therapeutic drug product that is administered to the patient, in addition to the vector tool used to create it.

Key Claims at a Glance

• The complaint asserts independent claims 1 and 11, along with dependent claims 2, 5, 7-8, and 15. Compl. ¶198
• Independent Claim 1 is directed to a composition of matter, with the following essential elements:
  • An isolated mammalian hematopoietic progenitor cell or an isolated mammalian stem cell.
  • The cell comprises a recombinant lentiviral vector.
  • The vector contains a nucleic acid encoding a functional globin operably linked to a 3.2-kb LCR fragment that "consists essentially of" the three specific HS2, HS3, and HS4 fragments. '061 Patent, claim 1
• Independent Claim 11 is directed to a method, with the following essential elements:
  • A method for making a mammalian hematopoietic progenitor cell or stem cell composition.
  • The method comprises (a) preparing the recombinant lentiviral vector with the claimed globin gene and LCR structure.
  • The method further comprises (b) obtaining the hematopoietic cells from a mammal and (c) transducing those cells with the vector. '061 Patent, claim 11

III. The Accused Instrumentality

Product Identification

The accused instrumentality is Defendant Bluebird's betibeglogene autotemcel (beti-cel) gene therapy, which is manufactured with and contains the BB305 lentiviral vector. Compl. ¶5 The product has been marketed under the brand names ZYNTEGLO® and LENTIGLOBIN®. Compl. ¶5 Compl. ¶111

Functionality and Market Context

Beti-cel is a one-time gene therapy intended for the treatment of transfusion-dependent β-thalassemia. Compl. ¶98 Compl. ¶103 The complaint alleges Bluebird is engaging in extensive commercialization activities in the U.S. and Europe, including stock-piling, ramp-up manufacturing, and developing "go-to-market" strategies in anticipation of FDA approval. Compl. ¶¶103-110 The FDA granted the therapy Breakthrough Therapy designation in 2015 and accepted Bluebird's Biologics License Application (BLA) for priority review. Compl. ¶98 Compl. ¶100 The therapy is projected to cost over $2 million per patient. Compl. ¶134

IV. Analysis of Infringement Allegations

The complaint alleges infringement of both the '179 and '061 Patents but states that detailed claim charts are provided in Exhibits L and M, which were not included with the filed document. Compl. ¶186 Compl. ¶198 In the absence of these exhibits, the infringement theory is summarized from the complaint's narrative allegations.

No probative visual evidence provided in complaint.

'179 Patent Infringement Allegations
The complaint alleges that Bluebird's BB305 Vector directly infringes at least claims 1 and 23 of the '179 Patent, either literally or under the doctrine of equivalents. Compl. ¶182 Compl. ¶186 The core of the infringement theory is that the BB305 Vector is a "recombinant lentiviral vector" that embodies the invention claimed in the '179 Patent. Compl. ¶183 This includes having a region encoding a functional β-globin gene operably linked to large portions of the β-globin LCR, including the claimed HS2, HS3, and HS4 sites, which provides for expression of β-globin in vivo. Compl. ¶183 The complaint recites the elements of independent claims 1 and 23, which define the required LCR structure, and asserts that the BB305 Vector meets these limitations. Compl. ¶¶184-186

'061 Patent Infringement Allegations
The complaint alleges that Bluebird's activities related to the BB305 Vector and the resulting beti-cel product infringe at least claims 1-2, 5, 7-8, 11, and 15 of the '061 Patent. Compl. ¶198 The infringement theory covers both the product and the method of making it. The infringement of product claim 1 is based on the allegation that the beti-cel therapy consists of isolated hematopoietic stem cells that have been modified to contain the infringing BB305 Vector. Compl. ¶196 The infringement of method claim 11 is based on the allegation that Bluebird's manufacturing process for beti-cel involves the claimed steps of preparing the vector and transducing the cells. Compl. ¶197

• Identified Points of Contention:
  • Scope Questions: A central question will be whether the specific genetic construct of the BB305 Vector's LCR falls within the scope of the claim term "consists essentially of three contiguous nucleotide fragments." The analysis will likely focus on whether any elements in the BB305 Vector, beyond the three recited LCR fragments, materially alter the basic and novel properties of the claimed invention.
  • Technical Questions: The case will require a detailed factual comparison between the sequence and structure of the BB305 Vector and the limitations of the asserted claims. A key evidentiary question is what the precise structure of the BB305 Vector is and whether its β-globin gene variant (βA-T87Q) meets the definition of a "functional globin gene" as contemplated by the patents.

V. Key Claim Terms for Construction

• The Term: "consists essentially of"

• Context and Importance: This transitional phrase, present in the independent claims of both patents, is critical for defining the scope of the LCR element. Infringement will depend on whether the BB305 Vector's LCR contains additional, unrecited components and, if so, whether those components "materially affect the basic and novel characteristics" of the claimed LCR fragment. Practitioners may focus on this term because it is a well-established term of art that creates a middle ground between the open-ended "comprising" and the closed "consisting of."

• Intrinsic Evidence for Interpretation:

  • Evidence for a Broader Interpretation: A party could argue that the "basic and novel characteristics" are simply the achievement of in vivo globin expression, as stated in the claim itself. '179 Patent, claim 1 Under this view, additional elements that do not prevent expression would not be material.
  • Evidence for a Narrower Interpretation: A party could point to the specification's emphasis on achieving "therapeutically meaningful levels" of globin and avoiding silencing as the key characteristics. '179 Patent, col. 1:40-44 '179 Patent, col. 7:20-23 They may argue that specific embodiments like the TNS9 vector '179 Patent, col. 3:9-26 define the expected performance, and any additional elements in an accused product that alter that performance level or stability are material.

• The Term: "functional globin gene"

• Context and Importance: The BB305 Vector uses a specifically engineered variant of the β-globin gene (βA-T87Q). Whether this variant qualifies as "functional" under the patent's definition will be a key point of dispute.

• Intrinsic Evidence for Interpretation:

  • Evidence for a Broader Interpretation: The specification defines the term as a sequence whose expression "does not produce a hemoglobinopathy phenotype, and which is effective to provide therapeutic benefits to an individual with a defective globin gene." '179 Patent, col. 2:42-46 An argument could be made that any gene variant meeting this therapeutic goal qualifies.
  • Evidence for a Narrower Interpretation: The specification also states the gene may encode a "wild-type globin" or a "mutant form... with superior properties." '179 Patent, col. 2:47-50 A party could argue that the βA-T87Q variant does not provide superior properties and is sufficiently different from wild-type to fall outside the intended scope.

VI. Other Allegations

• Indirect Infringement: The complaint alleges that Defendant Third Rock Ventures induced Bluebird's direct infringement. Compl. ¶¶142-179 The allegations are based on Third Rock's purported knowledge of the patents and SRT's license dating back to 2009, prior to Bluebird's formation. Compl. ¶142 Compl. ¶144 The complaint alleges that Third Rock actively participated in the creation of Bluebird for the purpose of commercializing an infringing vector and cites email correspondence and business dealings as evidence of specific intent to induce infringement. Compl. ¶149 Compl. ¶159 Compl. ¶161
• Willful Infringement: The complaint alleges willful infringement against both Defendants. The claim against Bluebird is based on its alleged knowledge of the patents from their issuance, including citing the '179 patent's publication as prior art to its own patent application, and its knowledge of SRT's exclusive license. Compl. ¶¶136-139 The willfulness claim against Third Rock is tied to the inducement allegations, asserting that it acted with knowledge of the patents and an intent to create a company that would infringe them. Compl. ¶177

VII. Analyst's Conclusion: Key Questions for the Case

• A threshold legal question will concern standing to sue: will the court find that the 2020 settlement agreement transferred "all substantial rights" in the patents to SRT, allowing it to sue for infringement in its own name, or will it require the patent owner, MSKCC, to be joined to the case?
• A core technical issue will be one of claim scope: can the term "consists essentially of", which modifies the claimed LCR fragment, be interpreted to read on the specific genetic architecture of Bluebird's BB305 vector? The resolution will depend on the court's construction of the term and a factual analysis of whether any additional elements in the BB305 vector materially alter the invention's fundamental characteristics.
• A dispositive issue for damages and equitable relief will be the relevance of the parties' contentious history: does the detailed narrative of pre-suit interactions, alleged competitive intelligence gathering, and the founding of Bluebird provide sufficient evidence to establish the specific intent required for induced infringement and the egregious conduct necessary for a finding of willfulness?